Characteristics of NPM1− MN, NPM1+ MN, and NPM1+ AML cohorts
| . | NPM1− MN (n = 95) . | NPM1+ MN (n = 45) . | NPM1+ AML (n = 119) . |
|---|---|---|---|
| Patient characteristics | |||
| Median age (range), y | 68 (38-84)* | 63 (36-96) | 61 (15-85) |
| Male:female | 1.9 | 1.0 | 0.75 |
| Clinical parameters | |||
| Hemoglobin, median (range), g/dL | 9.7 (4.8-15.9) | 9.0 (6.1-12.7) | 9.0 (5.7-15) |
| WBC, median (range), ×109/L | 3.5 (0.6-69.4) | 3.3 (1.2-225) | 21 (0.69-340)* |
| Platelet count, median (range), ×109/L | 84 (15-808) | 79 (15-607) | 72 (10-356) |
| Median of BM cellularity (range), % | 70 (10-95) | 80 (10-100) | 90 (30-98)* |
| Median of BM blasts (range), % | 8 (1-18) | 10 (1-19) | 73 (21-96)* |
| Diagnosis, n (%) | |||
| MDS non-EB | 5 (5) | 2 (4) | NA |
| MDS-EB | 55 (58) | 24 (53) | NA |
| CMML | 16 (17) | 9 (20) | NA |
| MDS/MPN (non-CMML) | 8 (8) | 5 (11) | NA |
| t-MN | 11 (12) | 5 (11) | NA |
| AML | NA | NA | 119 (100) |
| IPSS-R scores (MDS cases only), median (range) | 5.0 (1.0-10.0) | 5.0 (1.5-7.0) | NA |
| Outcome | |||
| Median follow-up time (range), mo | 19.4 (0.3-57) | 10 (0.07-70) | 24 (0.13-125) |
| Alive at last follow-up, n (%) | 53 (56) | 29 (64) | 67 (56) |
| Progression to AML, n (%) | 30 (32) | 20 (44) | NA |
| Median time to progression (range), mo | 6.3 (1.7-43) | 5.2 (0.4-17.5) | NA |
| Received upfront HMA therapy, n (%) | 55 (58) | 33 (73) | 5 (4) |
| Received upfront induction chemotherapy, n (%) | 0 (0) | 3 (7) | 113 (95) |
| Received SCT at any time, n (%) | 44 (46) | 19 (42) | 67 (56) |
| . | NPM1− MN (n = 95) . | NPM1+ MN (n = 45) . | NPM1+ AML (n = 119) . |
|---|---|---|---|
| Patient characteristics | |||
| Median age (range), y | 68 (38-84)* | 63 (36-96) | 61 (15-85) |
| Male:female | 1.9 | 1.0 | 0.75 |
| Clinical parameters | |||
| Hemoglobin, median (range), g/dL | 9.7 (4.8-15.9) | 9.0 (6.1-12.7) | 9.0 (5.7-15) |
| WBC, median (range), ×109/L | 3.5 (0.6-69.4) | 3.3 (1.2-225) | 21 (0.69-340)* |
| Platelet count, median (range), ×109/L | 84 (15-808) | 79 (15-607) | 72 (10-356) |
| Median of BM cellularity (range), % | 70 (10-95) | 80 (10-100) | 90 (30-98)* |
| Median of BM blasts (range), % | 8 (1-18) | 10 (1-19) | 73 (21-96)* |
| Diagnosis, n (%) | |||
| MDS non-EB | 5 (5) | 2 (4) | NA |
| MDS-EB | 55 (58) | 24 (53) | NA |
| CMML | 16 (17) | 9 (20) | NA |
| MDS/MPN (non-CMML) | 8 (8) | 5 (11) | NA |
| t-MN | 11 (12) | 5 (11) | NA |
| AML | NA | NA | 119 (100) |
| IPSS-R scores (MDS cases only), median (range) | 5.0 (1.0-10.0) | 5.0 (1.5-7.0) | NA |
| Outcome | |||
| Median follow-up time (range), mo | 19.4 (0.3-57) | 10 (0.07-70) | 24 (0.13-125) |
| Alive at last follow-up, n (%) | 53 (56) | 29 (64) | 67 (56) |
| Progression to AML, n (%) | 30 (32) | 20 (44) | NA |
| Median time to progression (range), mo | 6.3 (1.7-43) | 5.2 (0.4-17.5) | NA |
| Received upfront HMA therapy, n (%) | 55 (58) | 33 (73) | 5 (4) |
| Received upfront induction chemotherapy, n (%) | 0 (0) | 3 (7) | 113 (95) |
| Received SCT at any time, n (%) | 44 (46) | 19 (42) | 67 (56) |
BM, bone marrow; EB, excess blasts; NA, not available; t-MN, therapy-related myeloid neoplasm.
P < .05 for difference in comparison with NPM1+ MN group (Mann-Whitney U test).